Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

We showed previously that cAMP response element-binding protein (CREB) within the nucleus accumbens (NAc) of rats regulates immobility in the forced swim test (FST), an assay used to study depression. Because CREB regulates expression of dynorphin (which acts at kappa-opioid receptors) in NAc neurons, these findings raised the possibility that kappa-receptors mediate immobility behaviors in the FST. Here, we report that i.c.v. administration of the kappa-antagonist nor-binaltorphimine dose dependently decreased immobility in the FST, suggesting that it has antidepressant-like effects. Implicating a specific effect at kappa-receptors, similar antidepressant-like effects were seen after treatment with either of two novel, structurally dissimilar kappa-antagonists: 5'-guanidinonaltrindole, which was effective after i.c.v. but not systemic treatment, and 5'-acetamidinoethylnaltrindole (ANTI), which was potent and effective after systemic treatment. The behavioral effects of the kappa-antagonists resembled those of tricyclic antidepressants (desipramine) and selective serotonin reuptake inhibitors (fluoxetine and citalopram). Conversely, systemic administration of the kappa-agonist [5alpha,7alpha,8beta]-N-methyl-N-[7-[1-pyrrolidinyl]-1-oxaspiro[4.5]dec8-yl]-benzenacetamide (U-69593) dose dependently increased immobility in the FST, consistent with prodepressant-like effects. The effects of the kappa-ligands in the FST were not correlated with nonspecific effects on locomotor activity. Furthermore, the most potent and effective kappa-antagonist (ANTI) did not affect the rewarding impact of lateral hypothalamic brain stimulation at a dose with strong antidepressant-like effects. These findings are consistent with the hypothesis that CREB-mediated induction of dynorphin in the NAc "triggers" immobility behavior in the FST. Furthermore, they raise the possibility that kappa-antagonists may have efficacy as antidepressants, but lack stimulant or reward-related effects.

[1]  S. Hyman,et al.  Neuronal adaptation to amphetamine and dopamine: Molecular mechanisms of prodynorphin gene regulation in rat striatum , 1995, Neuron.

[2]  G. Chiara,et al.  Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression , 1999, Biological Psychiatry.

[3]  H. Emrich,et al.  Psychotomimesis mediated by kappa opiate receptors , 1986, Science.

[4]  P. Renshaw,et al.  Antidepressant-like effects of cytidine in the forced swim test in rats , 2002, Biological Psychiatry.

[5]  R. Wise,et al.  Microinjections of phencyclidine (PCP) and related drugs into nucleus accumbens shell potentiate medial forebrain bundle brain stimulation reward , 1996, Psychopharmacology.

[6]  F. J. White,et al.  Whole-Cell Plasticity in Cocaine Withdrawal: Reduced Sodium Currents in Nucleus Accumbens Neurons , 1998, The Journal of Neuroscience.

[7]  M. Todtenkopf,et al.  Repeated Exposure to Rewarding Brain Stimulation Downregulates GluR1 Expression in the Ventral Tegmental Area , 2001, Neuropsychopharmacology.

[8]  T. Shippenberg,et al.  Sensitization to the Behavioral Effects of Cocaine: Modulation by Dynorphin and κ-Opioid Receptor Agonists , 1997, Pharmacology Biochemistry and Behavior.

[9]  G F Koob,et al.  Drug dependence: stress and dysregulation of brain reward pathways. , 1998, Drug and alcohol dependence.

[10]  Eric J. Nestler,et al.  Inhibition of cAMP Response Element-Binding Protein or Dynorphin in the Nucleus Accumbens Produces an Antidepressant-Like Effect , 2002, The Journal of Neuroscience.

[11]  R. Wise Neuroleptics and operant behavior: The anhedonia hypothesis , 1982, Behavioral and Brain Sciences.

[12]  G. Koob,et al.  Desmethylimipramine attenuates cocaine withdrawal in rats , 2005, Psychopharmacology.

[13]  C. Kornetsky,et al.  Acute and Chronic Fluoxetine Treatment Decreases the Sensitivity of Rats to Rewarding Brain Stimulation , 1998, Pharmacology Biochemistry and Behavior.

[14]  P. Rompré,et al.  The curve-shift paradigm in self-stimulation , 1986, Physiology & Behavior.

[15]  A. Kelley,et al.  Acute and chronic desipramine treatment effects on rewarding electrical stimulation of the lateral hypothalamus , 1990, Pharmacology Biochemistry and Behavior.

[16]  V. Pickel,et al.  Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  D. Jones,et al.  Long term kappa-opioid receptor blockade following nor-binaltorphimine. , 1992, European journal of pharmacology.

[18]  M. Kuhar,et al.  Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. , 1989, The Journal of pharmacology and experimental therapeutics.

[19]  R. Duman Synaptic plasticity and mood disorders , 2002, Molecular Psychiatry.

[20]  W. Drevets,et al.  The cellular neurobiology of depression , 2001, Nature Medicine.

[21]  E. Nestler,et al.  Altered Responsiveness to Cocaine and Increased Immobility in the Forced Swim Test Associated with Elevated cAMP Response Element-Binding Protein Expression in Nucleus Accumbens , 2001, The Journal of Neuroscience.

[22]  N. Hiroi,et al.  Regulation of cocaine reward by CREB. , 1998, Science.

[23]  R. Spanagel,et al.  Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat. , 1993, Neuroscience letters.

[24]  R. M. Jones,et al.  5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. , 2000, European journal of pharmacology.

[25]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. M. Jones,et al.  Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. , 2000, Journal of medicinal chemistry.

[27]  G F Koob,et al.  Withdrawal following cocaine self‐administration decreases regional cerebral metabolic rate in critical brain reward regions , 1993, Synapse.

[28]  S. D. Glick,et al.  U50,488, a κ opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats , 1994, Neuroscience Letters.

[29]  F. Goodwin,et al.  The effects of cocaine on depressed patients. , 1974, The American journal of psychiatry.

[30]  A. Levine,et al.  The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats , 2001, Brain Research.

[31]  R. Wise Drug-activation of brain reward pathways. , 1998, Drug and alcohol dependence.

[32]  Michael Rickels,et al.  Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants , 1995, Psychopharmacology.

[33]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[34]  T. Kemper,et al.  Dorsal raphe, substantia nigra and locus coeruleus: Interconnections with each other and the neostriatum , 1977, Brain Research Bulletin.

[35]  R. Wise,et al.  Rewarding Actions of Phencyclidine and Related Drugs in Nucleus Accumbens Shell and Frontal Cortex , 1996, The Journal of Neuroscience.

[36]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[37]  N. Mello,et al.  Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys , 2002, Psychopharmacology.

[38]  T. Robinson,et al.  Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats , 2005, Psychopharmacology.

[39]  P. Jatlow,et al.  Desipramine facilitation of initial cocaine abstinence. , 1989, Archives of general psychiatry.